CE20 - Biologie des animaux, des organismes photosynthétiques et des microorganismes

Diatom Glyco-Engineering for New Therapeutical Applications – DAGENTA

Submission summary

Monoclonal antibodies (mAb) used to treat cancers, immune and infectious diseases represent a multibillion dollar industry. Chinese Hamster Ovary cells are currently the gold standard. However, high expense, potential virus contamination and mAb heterogeneity represent major drawbacks that drive scientists to seek alternatives. Among these, the diatom P. tricornutum represent an option because of (i) its robustness in industrial process, (ii) its ability to be cultivated in mixotrophy, (iii) its genome availability and possibility to be genetically engineered. The proof of concept in P. tricornutum has already been exemplified through the production of a glycosylated mAb. A human-like N-glycosylation is now required for mAb optimal safety and efficacy when used in human therapies. Therefore, we propose to engineer the N-glycosylation pathway of P. tricornutum by gene silencing and expressing heterologous enzymes, thus allowing galactosylated algae-made mAb production.

Project coordinator

Madame Muriel BARDOR (GLYCOBIOLOGIE ET MATRICE EXTRACELLULAIRE VEGETALE)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

UGSF UMR 8576 - Unité de glycobiologie structurale et fonctionnelle
TWB Toulouse White Biotechnology
e-Zyvec / R et D
GlycoMEV GLYCOBIOLOGIE ET MATRICE EXTRACELLULAIRE VEGETALE

Help of the ANR 617,838 euros
Beginning and duration of the scientific project: January 2022 - 48 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter